Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

Homocysteine: To screen and treat or to wait and see?

Jacques Genest, Marie-Chantal Audelin and Eva Lonn
CMAJ July 11, 2000 163 (1) 37-38;
Jacques Genest Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Chantal Audelin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Lonn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Novel risk factors for cardiovascular diseases, including infectious agents such as Chlamydia pneumoniae and Helicobacter pylori, inflammatory mediators such as C-reactive protein and interleukin-6, and hemostatic markers, are being uncovered at a rapid pace. A high homocysteine level is one of the most recent risk factors to be identified. The measurement of total plasma (or serum) homocysteine (tHcy) represents the sum of oxidized (as homocysteine or the homocysteine-cysteine mixed disulfide) and protein-bound homocysteine. Despite extensive research the mechanisms by which homocysteine causes arterial damage are not fully understood. Homocysteine contains a reactive sulfydryl group than can react with plasma constituents, and this may promote oxidative damage and induce the oxidation of low-density lipoprotein. An elevated homocysteine level induces thrombogenicity, causes a procoagulant state and promotes the proliferation of smooth muscle cells.

The epidemiological data linking tHcy to atherosclerosis is extensive in case-control studies, but the strength of this association is weaker in prospective studies. Thus, the causal relationship between tHcy and heart disease is not as strong as one would like to make recommendations regarding screening and treatment for the prevention of cardiovascular diseases.

tHcy levels are associated with sex (i.e., levels are higher in men), postmenopausal status in women, increasing age, nutritional intake (and plasma levels) of vitamins B12, B6 and folate, renal function, genetic predisposition and thyroid function.1 Some medications, such as niacin, methotrexate and fenofibrate, can also cause elevated tHcy levels.[1, 2]

Because tHcy level is a continuous biochemical variable, normality is difficult to define. Hyperhomocysteinemia is usually defined as a tHcy level in the 90th or 95th percentile of a control population; in most studies, this is approximately 15 μmol/L. In high risk patients this may be too high and some experts recommend a level of 10 μmol/L as a therapeutic target;[3, 4] others are more conservative.5 The treatment of elevated tHcy is relatively simple. Vitamin supplementation, starting with folate (0.4-5 mg/day) and adding vitamin B6 (25-50 mg) and B12 (0.5-1.0 mg) is highly effective in lowering levels.

The enthusiasm of patients to embrace novel and "natural" treatments is, well, natural. We have learned, however, that vitamin supplementation may not be useful,[6, 7] and when taken in very large doses may potentially be harmful.

So where do things stand with homocysteine? Should we bother to screen and treat elevated homocysteine levels? At present, there are 3 approaches:

• don't test and don't treat

• treat everyone because it makes sense and treatment is cheap

• consider screening patients with established atherosclerotic disease and initiating treatment if the tHcy level is above 10 μmol/L

There are currently at least a dozen large-scale studies being conducted in the United States, Canada and Europe (especially in the Scandinavian countries) to examine the effects of lowering tHcy on cardiovascular morbidity and mortality.8 Roughly 45 000 patients are currently enrolled in trials on the effects of vitamin supplementation on cardiac events and 15 000 more in trials on stroke prevention. In Canada the HOPE-TOO trial will follow the path of the HOPE trial[7, 8] and attempt to identify the role of vitamin supplementation in cardiovascular disease prevention.

In the interim Drs. Booth and Wang, with the Canadian Task Force on Preventive Health Care,9 review the information available to date (see page 21) and advise that caution is warranted in extrapolating directly from imperfect epidemiological data. The American Heart Association,3 the International Task Force on the Prevention of Coronary Artery Disease,5 the Canadian Cardiovascular Society4 and the Heart and Stroke Foundation of Canada agree that we must wait for the results of ongoing clinical studies before making any change to public health policy. We must also encourage those conducting clinical studies to study the potential benefits of lowering plasma tHcy levels in the prevention of cardiovascular diseases. Clinical trialists have the day ... and the last say.

In the absence of definitive evidence it might be best to work hard at collecting the data and exercise caution in our endorsement of therapies that appear to make sense. In the meantime, a healthy diet rich in legumes, orange juice and green leafy vegetables is a recommendation that has withstood the test of time. The dilemma lies in the treatment of moderately severe hyperhomocysteinemia, once identified. We know diet alone is insufficient to normalize tHcy levels. Until the data are in, physicians must use their best judgement. Our enthusiasm for the potential of novel preventive strategies should not diminish our diligence in implementing simple health measures and prescribing treatments proven to effectively reduce the risk for cardiovascular diseases.

Competing interests: None declared for Drs. Audelin and Lonn. Dr. Genest received speaker fees and travel assistance from various pharmaceutical companies to attend conferences on related topics.

Footnotes

  • See related article page 21

    Reprints requests to: Dr. Jacques Genest, Chief, Cardiology Division, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Ave. W, Montreal QC H3A 1A1; fax 514 982-0686; jacques.genest@muhc.mcgill.ca

References

  1. 1.↵
    Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
    OpenUrlCrossRefPubMed
  2. 2.↵
    de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine. Lancet 1999;353:209-10.
    OpenUrl
  3. 3.↵
    Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-82.
    OpenUrlFREE Full Text
  4. 4.↵
    Genest J Jr. Emerging risk factors associated with cardiovascular diseases. Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. Can J Cardiol 1999;15(Suppl G):73G-6G.
    OpenUrlPubMed
  5. 5.↵
    International Task Force for the Prevention of Coronary Artery Disease. Coronary artery disease: reducing the risk. Nutr Metab Cardiovasc Dis 1998;8:229.
  6. 6.↵
    Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1991;58:668-75.
    OpenUrl
  7. 7.↵
    Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Booth GL, Wang EEL, with the Canadian Task Force on Preventive Health Care. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. CMAJ 2000;163(1):21-9.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 1
11 Jul 2000
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (85-92)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Homocysteine: To screen and treat or to wait and see?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Homocysteine: To screen and treat or to wait and see?
Jacques Genest, Marie-Chantal Audelin, Eva Lonn
CMAJ Jul 2000, 163 (1) 37-38;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Homocysteine: To screen and treat or to wait and see?
Jacques Genest, Marie-Chantal Audelin, Eva Lonn
CMAJ Jul 2000, 163 (1) 37-38;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Reducing Coronary Artery Disease by Decreasing Homocysteine Levels
  • Google Scholar

More in this TOC Section

  • Antiracism as a foundational competency: reimagining CanMEDS through an antiracist lens
  • Keeping the front door open: ensuring access to primary care for all in Canada
  • Improving post-tuberculosis care in Canada
Show more Commentary

Similar Articles

Collections

  • Topics
    • Cardiology: ischemic heart disease
    • Nutrition
    • Screening & diagnostic tests

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire